Fluxion Biosciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Loan | Alive

Total Raised


Last Raised

$250K | 2 yrs ago

About Fluxion Biosciences

Fluxion Biosciences is a developer of precision solutions for life science research and diagnostics. Fluxion's liquid biopsy solutions are changing how cancer is detected and treated. Fluxion's pioneering liquid biopsy technologies include the IsoFlux CTC Liquid Biopsy System, ERASE-Seq ultra-sensitive variant caller, and the Spotlight 59 NGS Oncology Panel for cancer mutation detection from cell-free circulating tumor DNA. Fluxion's technologies are used globally by cancer centers developing new tests for early cancer detection and patient monitoring.

Fluxion Biosciences Headquarter Location

1600 Harbor Bay Parkway #140

Alameda, California, 94502,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Fluxion Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Fluxion Biosciences is included in 4 Expert Collections, including Cancer.



3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'


Medical Devices

8,082 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Health IT

7,900 items

Fluxion Biosciences Patents

Fluxion Biosciences has filed 7 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • DNA
  • Genetics
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Genetics, Biotechnology, DNA, Transcription factors


Application Date


Grant Date



Related Topics

Molecular biology, Genetics, Biotechnology, DNA, Transcription factors



Latest Fluxion Biosciences News

Global Needle Biopsy Market To Reach $850.50 Million With Industry Analysis, Post COVID-19 Impact, Emerging Trends,Forecast By Thermo Fisher Scientific Inc., Biocept, Inc., Bio-Rad Laboratories, Inc., Fluxion Biosciences, Inc

Jul 14, 2021

Search jobs 14-Jul-2021 Global Needle Biopsy Market To Reach $850.50 Million With Industry Analysis, Post COVID-19 Impact, Emerging Trends,Forecast By Thermo Fisher Scientific Inc., Biocept, Inc., Bio-Rad Laboratories, Inc., Fluxion Biosciences, Inc Data Bridge Market Research offers ” Needle Biopsy Global Market Report 2021: COVID-19 Growth And Change” in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country. It also compares the market’s historic and forecast growth, and highlights important trend s and strategies that players in the market can adopt. The Needle Biopsy market report describes and explains the global Needle Biopsy market and covers 2015 to 2020, termed the historic period, and 2021 to 2028 termed the forecast period, along with further forecasts for the period 2021-2028. The report evaluates the market across each region and for the major economies within each region. Download Free Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-needle-biopsy-market The needle biopsy market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to USD 850.50 million by 2028 and will grow at a CAGR of 5.81% in the above mentioned forecast period. The major players covered in the needle biopsy market report are QIAGEN, Boston Scientific Corporation, Global Needle Biopsy Market Drivers: The high incidence of breast and lung cancer is amongst the significant factors expected to fuel the growth and demand of needle biopsy market. In addition, the rapid rise in preference for minimally invasive surgeries and various initiatives undertaken by government and global health organizations are also anticipated to push the growth in the global needle biopsy market over the forecast period of 2021 to 2028. Likewise, the rapid technological advancement and development and rise in awareness regarding early detection of  breast cancer  are also projected to lift the growth of the market. Furthermore, the increase in the number of breast cancer screening programs and increase in  disposable  income are also expected to act as significant factors which will flourish the growth of the needle biopsy market. The emergence of needle biopsy and promising clinical trials along with the improved reimbursement scenario are expected to offer significant growth opportunities for the needle biopsy market in the forecast period of 2021 to 2028. Global Needle Biopsy Market Restraints: However, the rapid development of ultrasensitive imaging technologies such as magnetic resonance imaging (MRI) and computed tomography (CT)  along with the product recalls are estimated to limit the growth of the needle biopsy market, whereas, the underdeveloped healthcare infrastructure and lack of resources in developing countries can challenge the growth of the needle biopsy market. To Understand How Covid-19 Impact Is Covered In This Report, Get Free Covid-19 Sample @ https://www.databridgemarketresearch.com/covid-19-impact/global-needle-biopsy-market Global Needle Biopsy Market Scope and Market Size The needle biopsy market is segmented on the basis of type, utility and application. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications. Based on type, the needle biopsy market is segmented into fine-needle aspiration biopsy, core needle biopsy, vacuum-assisted biopsy and image-guided biopsy. The utility segment of the needle biopsy market is segmented into disposable and reusable. Based on application, the needle biopsy market is segmented into  tumor ,  infection , inflammation and others. Table of Content: Chapter 2: Needle Biopsy market Economic Impact Chapter 3: Competition by Manufacturer Chapter 4: Production, Revenue (Value) by Region (2021-2028) Chapter 5: Supply (Production), Consumption, Export, Import by Regions (2021-2028) Chapter 6: Production, Revenue (Value), Price Trend by Type Chapter 7: market Analysis by Application Chapter 8: Needle Biopsy Market by Manufacturing Cost Analysis Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers Chapter 10: Marketing Strategy Analysis, Distributors/Traders Chapter 11: Needle Biopsy Market Geographic Analyses Chapter 11.1: North America Needle Biopsy Market Country Level Analysis The needle biopsy market is analyzed and market size insights and trends are provided by country, type, utility and application as referenced above. The countries covered in the needle biopsy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America. North America region leads the needle biopsy market owing to the maximum market share of U.S. due to favorable reimbursement scenarios and high expenditure on healthcare. Asia-Pacific is expected to expand at a significant growth rate over the forecast period of 2021 to 2028 because of the large unmet needs is led by India and China. Strategic Key Insights of the Needle Biopsy Report: • Production Analysis – Production is analyzed with respect to different regions, types, and applications. Here, price analysis of different market key players is also covered. • Sales and Revenue Analysis – Both, sales and revenue are taken into account for the different regions of the Needle Biopsy market. Price is another major aspect that is important in the revenue generation, and hence it is also assessed in this section for the various regions. • Supply and Consumption – In continuation of the sales analysis, this section examines supply and consumption for the Needle Biopsy Market. This part also highlights the gap between supply and consumption. Moreover, import and export figures are also given in this part. Competitors – In this section, various leading players of the healthcare industry are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue. • Analytical Tools – The Needle Biopsy market report includes the specifically studied and evaluated information of the key players and their market scope using several analytical tools, including SWOT analysis, Porter’s five forces analysis, investment return analysis, and feasibility study. These tools have been used to proficiently study the growth of the major industry participants. • The 360-degree Needle Biopsy overview based on a global and regional level. Market share, value, volume, and production capacity is analyzed on global, regional and country level. And the report is also a complete and useful guide for new market aspirants. • This report enhances decision making in view of noteworthy and gauging information also the drivers and limitations available of the market. Share Your Specific Research Requirements & related questions for a Needle Biopsy Report@ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-needle-biopsy-market Customization Available : Global Needle Biopsy Market Data Bridge Market Research  is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report. About Us: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing  sopan.gedam@databridgemarketresearch.com  . We are content with our glorious 99.9 % client satisfying rate. Contact:

Fluxion Biosciences Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Fluxion Biosciences Rank

  • When was Fluxion Biosciences founded?

    Fluxion Biosciences was founded in 2005.

  • Where is Fluxion Biosciences's headquarters?

    Fluxion Biosciences's headquarters is located at 1600 Harbor Bay Parkway, Alameda.

  • What is Fluxion Biosciences's latest funding round?

    Fluxion Biosciences's latest funding round is Loan.

  • How much did Fluxion Biosciences raise?

    Fluxion Biosciences raised a total of $15.9M.

  • Who are Fluxion Biosciences's competitors?

    Competitors of Fluxion Biosciences include Parithera, Gentronix Limited, BioNano Genomics, Guava Technologies, Phylogeny, Sword Diagnostics, Aushon BioSystems, CytoBioscience, NMS Group, Cellix and 19 more.

You May Also Like

Sword Diagnostics

Sword Diagnostics is a life sciences company created in response to the needs of the research, pharmaceutical, and clinical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and diseased-related biological processes, today's life science tools are unable to effectively measure, quantify, and determine the ultimate value of these biological markers. Sword Diagnostics' technology is directly aimed at making it easier to understand these newly emerging biomarkers, as well as extending the utility of existing diagnostics assays. Sword's mission is to provide the next-generation detection technology to life scientists, enabling them to continue advances in medical research, drug discovery and the provision of health care products and services.

Genomic Solutions

The scientists at Genomic Solutions have a wealth of genomic, protein analysis and nano-liter dispensing application-based expertise that they would like to share with users. First select their area of research, followed by interest and then application, and finally, to the company's instrumentation which can help facilitate their research. Whether users are involved in the life science or biotechnology research community, the company's products will enable users to perform complex, high volume experiments at a lower cost and in less time than traditional techniques. You achieve rapid and less expensive drug discovery.

Gentronix Limited

Gentronix provides toxicology testing services for pharmaceuticals, agrochemicals, cosmetics, personal care and consumer products. The company enables major global brands to perform hazard and safety assessments, from early-stage discovery through to regulatory submission and approval.


Vivonetics a company created through Georgia Tech's VentureLab program. The company is developing applications for molecular beacon technology in life science research and drug discovery. Its initial focus is on probes to detect RNA in living cells.


PlexPress is a life science company doing work in gene expression analysis technology to advance biological science, drug discovery, crop science and diagnostics. PlexPress seeks to rapidly provide reliable information at low cost. Its products simultaneously measure multiple genes from multiple samples. PlexPress operates from Los Altos, California and Helsinki, Finland.

Echelon Biosciences Logo
Echelon Biosciences

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.